Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

November 15, 2005 (Vol. 25, No. 20)

Advancing Viral Vector-Based Technology

Applications Go Beyond Vaccines and Gene Therapy to include Drug Discovery Research

  • Introgen Therapeutic's (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic vaccine employs a patient's dendritic cells transfected with an adenoviral vector carrying the human p53 gene. It stimulates the immune ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.